BRIEF-Revive to start Phase 2b trial in gout after access to required capital

Tue May 10, 2016 7:13am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

May 10 (Reuters) - Revive Therapeutics Ltd

* Says will start its Phase 2B trial in gout when it has access to capital necessary to fund trial

* Over last several months, has taken necessary steps to reduce its monthly cash burn rate and streamline its operations Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)